Sequence information
Variant position: 159 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 503 The length of the canonical sequence.
Location on the sequence:
GLWHVRRRQEKQRGLHSELG
E SSLILKASEQGDSMLGDLLD
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human GLWHVRRRQEKQRGLHSELGE SSLILKASEQGDSMLGDLLD
Mouse GLWRVRRRQEKQRDLHSDLGE SSLILKASEQADSMLGDFLD
Rat GLWRVRRRQEKQRGLHSDLGE SSLILKASEQGDSMLGDFLV
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
22 – 503
Serine/threonine-protein kinase receptor R3
Topological domain
142 – 503
Cytoplasmic
Modified residue
155 – 155
Phosphoserine
Modified residue
160 – 160
Phosphoserine
Modified residue
161 – 161
Phosphoserine
Literature citations
Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension.
Pousada G.; Baloira A.; Vilarino C.; Cifrian J.M.; Valverde D.;
PLoS ONE 9:E100261-E100261(2014)
Cited for: VARIANTS ASN-8; VAL-59; VAL-159; CYS-225 AND ALA-396;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.